Illumina Stock Outlook: Is Wall Street Bullish or Bearish?

Barchart
Barchart kaynağında aç
Illumina Stock Outlook: Is Wall Street Bullish or Bearish?

Based in San Diego, California, Illumina, Inc. (ILMN) provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas and internationally. The company has a market cap of $29.9 billion and offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits; and more. 

Shares of Illumina have rallied the broader market over the past year, surging 68.7% compared to the S&P 500 Index’s ($SPX) 10% surge. Moreover, in 2026, the stock has grown by nearly 54.5%, also outperforming SPX’s 7.2% gain.    

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Zooming in further, the State Street Healthcare Select Sector SPDR ETF (XLV) has risen 22.1% over the past year, underperforming the stock. In 2026, XLV has surged 19.7% and lagged behind the stock. 

www.barchart.com

On Oct. 30, ILMN stock tanked nearly 18.6% following the release of its mixed Q3 2026 earnings. The company’s revenue for the quarter rose 4.2% from the prior year’s quarter to $1.1 billion, but missed the Street’s estimates. However, its adjusted EPS came in at $1.44, topping the consensus estimates. The company slightly lifted its revenue guidance for the full year to $4.65 billion and also raised its full-year adjusted EPS guidance to $5.43 at the midpoint. 

For the current year, ending in December, analysts expect ILMN’s EPS to rise 12.2% to $5.43 on a diluted basis. The company surpassed the consensus estimate in each of the last four quarters.      

According to 21 analysts covering ILMN stock, the consensus is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, one “Moderate Buy,” eight “Holds,” one “Moderate Sell,” and two “Strong Sells.” 

www.barchart.com

The configuration has grown more bearish over the past months, with the stock now having nine “Strong Buy” ratings, compared to 10 a month ago.    

On Nov. 5, Baird analyst Catherine Ramsey Schulte maintained a “Hold” rating for ILMN stock and lowered its price target from $286 to $236. 

ILMN’s mean price target of $268.38 offers 32.5% upside from the current market price. Its Street-high target of $365 implies a robust 80.1% upside from current levels.


On the date of publication, Aritra Gangopadhyay did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Realty Income vs. Agree Realty: Which REIT Wins on Dividends and Growth? Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares Amazon Is Building a Massive Shopping Data Repository to Compete With AI Agents. Shareholders Should Welcome the Move. Applied Materials Reports Another Double Beat in Q4. AMAT Stock Could Gain 66% From Here.